SlideShare a Scribd company logo
Control/Tracking Number: EPI-07-A-28-AHA
Activity: Abstract
Current Date/Time: 10/3/2006 4:02:55 PM

Prediction of the Framingham Risk Score and Coronary Heart Disease Risk in Extremely Obese Individuals.


Author Block: Robert C Lowe Sr., Jennifer Patzkowsky, Debbie Zimmerman, Polk County Schs, Winter Haven, FL; Phil
Chen, Cognoscenti Health Inst, Orlando, FL

Abstract:
The Framingham Risk Score (FRS) is widely used as a 10-year estimate of an individual’s risk of death due to myocardial
infarction (MI) and coronary heart disease (CHD). The variables in the FRS include age, total cholesterol (TC), HDL
cholesterol (HDL), systolic blood pressure (SBP), treatment for hypertension, and cigarette smoking. Current thinking
alludes to the development of CHD through risk factors associated wih the Metabolic Syndrome (MetS), i.e., elevated
                                                                       t
triglycerides (TG), waist circumference (WC), blood pressure (BP), glucose (BG) and decreased HDL. In addition to the
FRS, the ratio of TC to HDL cholesterol has been validated to estimate 10-year coronary heart disease risk (CHDR). The
purpose of this study was to explore the relationship between MetS risk factors, FRS, and CHDR in individuals classified
as extremely obese (EO). Seventy-three EO individuals (Age = 48 ± 9 yr; BMI = 40.7 ± 8.8) randomly selected to
participate in a weight loss program were used in this study. Multiple biometric measures, including those variables for
MS and FRS were measured or calculated. The data were analysed by multiple stepwise regression. Triglyceride (TG)
was the best predictor of FRS from a subset of MetS variables (Model 1; F1,70 = 40.41, p <0.00), however, it was a poor fit
(R2adj = 36%). The inclusion of HDL, TG, and WC produced the best fit for CHDR (Model 2; F3,68 = 26.35, p < 0.00) from
the subset of MetS variables and accounted for slightly half of the variance (R2adj = 52%). Although both Model 1 and
Model 2 were highly significant, they were not able to explain 64% and 48% of the model variance, respectively. Despite
the MetS risk factors being implicated in the development of CVD and CHD, these results suggest that using MetS
variables to predict the 10-year risk of dying from MI and CHD is not warranted.
:

Author Disclosure Block: R.C. Lowe, None; J. Patzkowsky, None; D. Zimmerman, None; P. Chen, None.

Unlabeled/Unapproved Disclosure (Complete):
  Please Select: : There are no unlabeled/unapproved uses of drugs or products


Category (Complete): Obesity
Keywords (Complete): Physical activity ; Obesity ; Exercise
Presentation Preference (Complete): Oral
Awards (Complete):
Connection Corner (Complete):
   : yes


Payment (Complete): Your credit card order has been processed on Tuesday 3 October 2006 at 3:58 PM.
Attached Files:
No Files Attached
Status: Complete

More Related Content

What's hot

HPPS : Heart Problem Prediction System using Machine Learning
HPPS : Heart Problem Prediction System using Machine LearningHPPS : Heart Problem Prediction System using Machine Learning
HPPS : Heart Problem Prediction System using Machine Learning
Nimai Chand Das Adhikari
 
New Year, New You: Give 2012 a Heart Healthy Start!
New Year, New You: Give 2012 a Heart Healthy Start!New Year, New You: Give 2012 a Heart Healthy Start!
New Year, New You: Give 2012 a Heart Healthy Start!
Regina Druz, MD, FACC
 
The Los Angeles Veterans Trial - A Negative Dietary Trial
The Los Angeles Veterans Trial - A Negative Dietary TrialThe Los Angeles Veterans Trial - A Negative Dietary Trial
The Los Angeles Veterans Trial - A Negative Dietary Trial
Zahccc
 
Raised Lipid Profile In Rheumatoid Arthritis- A Risk For CVD
Raised Lipid Profile In Rheumatoid Arthritis- A Risk For CVDRaised Lipid Profile In Rheumatoid Arthritis- A Risk For CVD
Raised Lipid Profile In Rheumatoid Arthritis- A Risk For CVD
iosrjce
 
Lung Transplantation For CF
Lung Transplantation For CFLung Transplantation For CF
Lung Transplantation For CF
Spectrum Health System
 
Cigarette smoking, systolic blood pressure, and cardiovascular diseases in th...
Cigarette smoking, systolic blood pressure, and cardiovascular diseases in th...Cigarette smoking, systolic blood pressure, and cardiovascular diseases in th...
Cigarette smoking, systolic blood pressure, and cardiovascular diseases in th...
SHAPE Society
 
Using Microsimulation to inform Targeted Cardiovascular Disease Prevention Po...
Using Microsimulation to inform Targeted Cardiovascular Disease Prevention Po...Using Microsimulation to inform Targeted Cardiovascular Disease Prevention Po...
Using Microsimulation to inform Targeted Cardiovascular Disease Prevention Po...
HMO Research Network
 
Template For Poster Presentation (Tysa)
Template For Poster Presentation (Tysa)Template For Poster Presentation (Tysa)
Template For Poster Presentation (Tysa)
drtanoybose
 
Fgf-23 and mortality risk in CKD
Fgf-23 and mortality risk in CKDFgf-23 and mortality risk in CKD
Fgf-23 and mortality risk in CKD
arunchawlamd
 
Lipidomics and Cardiovascular diseases
Lipidomics and Cardiovascular diseasesLipidomics and Cardiovascular diseases
Lipidomics and Cardiovascular diseases
PRAVEEN GUPTA
 
Poster13 laura Abell
Poster13 laura AbellPoster13 laura Abell
Poster13 laura Abell
Laura Abell
 
casestudy
casestudycasestudy
casestudy
Ran Zhou
 
The Metabolic Syndrome in a State Psychiatric Hospital Population 10.26.09
The Metabolic Syndrome in a State Psychiatric Hospital Population 10.26.09The Metabolic Syndrome in a State Psychiatric Hospital Population 10.26.09
The Metabolic Syndrome in a State Psychiatric Hospital Population 10.26.09
Leonard Davis Institute of Health Economics
 
La struttura della medicina di precisione
La struttura della medicina di precisioneLa struttura della medicina di precisione
La struttura della medicina di precisione
Fondazione Giannino Bassetti
 
Serum il17 and il6 levels in a sample of iraqi patients with rheumatoid arthr...
Serum il17 and il6 levels in a sample of iraqi patients with rheumatoid arthr...Serum il17 and il6 levels in a sample of iraqi patients with rheumatoid arthr...
Serum il17 and il6 levels in a sample of iraqi patients with rheumatoid arthr...
Alexander Decker
 
Avoidable Mortality and Health Disparities in the US 5.2.08
Avoidable Mortality and Health Disparities in the US 5.2.08Avoidable Mortality and Health Disparities in the US 5.2.08
Avoidable Mortality and Health Disparities in the US 5.2.08
Leonard Davis Institute of Health Economics
 
ACC 2015
ACC 2015ACC 2015
Polymorphisms rs1800587 and rs1143634 of the Interleukin-1α Gene are associat...
Polymorphisms rs1800587 and rs1143634 of the Interleukin-1α Gene are associat...Polymorphisms rs1800587 and rs1143634 of the Interleukin-1α Gene are associat...
Polymorphisms rs1800587 and rs1143634 of the Interleukin-1α Gene are associat...
science journals
 
Es v2n43
Es v2n43Es v2n43
251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium
Society for Heart Attack Prevention and Eradication
 

What's hot (20)

HPPS : Heart Problem Prediction System using Machine Learning
HPPS : Heart Problem Prediction System using Machine LearningHPPS : Heart Problem Prediction System using Machine Learning
HPPS : Heart Problem Prediction System using Machine Learning
 
New Year, New You: Give 2012 a Heart Healthy Start!
New Year, New You: Give 2012 a Heart Healthy Start!New Year, New You: Give 2012 a Heart Healthy Start!
New Year, New You: Give 2012 a Heart Healthy Start!
 
The Los Angeles Veterans Trial - A Negative Dietary Trial
The Los Angeles Veterans Trial - A Negative Dietary TrialThe Los Angeles Veterans Trial - A Negative Dietary Trial
The Los Angeles Veterans Trial - A Negative Dietary Trial
 
Raised Lipid Profile In Rheumatoid Arthritis- A Risk For CVD
Raised Lipid Profile In Rheumatoid Arthritis- A Risk For CVDRaised Lipid Profile In Rheumatoid Arthritis- A Risk For CVD
Raised Lipid Profile In Rheumatoid Arthritis- A Risk For CVD
 
Lung Transplantation For CF
Lung Transplantation For CFLung Transplantation For CF
Lung Transplantation For CF
 
Cigarette smoking, systolic blood pressure, and cardiovascular diseases in th...
Cigarette smoking, systolic blood pressure, and cardiovascular diseases in th...Cigarette smoking, systolic blood pressure, and cardiovascular diseases in th...
Cigarette smoking, systolic blood pressure, and cardiovascular diseases in th...
 
Using Microsimulation to inform Targeted Cardiovascular Disease Prevention Po...
Using Microsimulation to inform Targeted Cardiovascular Disease Prevention Po...Using Microsimulation to inform Targeted Cardiovascular Disease Prevention Po...
Using Microsimulation to inform Targeted Cardiovascular Disease Prevention Po...
 
Template For Poster Presentation (Tysa)
Template For Poster Presentation (Tysa)Template For Poster Presentation (Tysa)
Template For Poster Presentation (Tysa)
 
Fgf-23 and mortality risk in CKD
Fgf-23 and mortality risk in CKDFgf-23 and mortality risk in CKD
Fgf-23 and mortality risk in CKD
 
Lipidomics and Cardiovascular diseases
Lipidomics and Cardiovascular diseasesLipidomics and Cardiovascular diseases
Lipidomics and Cardiovascular diseases
 
Poster13 laura Abell
Poster13 laura AbellPoster13 laura Abell
Poster13 laura Abell
 
casestudy
casestudycasestudy
casestudy
 
The Metabolic Syndrome in a State Psychiatric Hospital Population 10.26.09
The Metabolic Syndrome in a State Psychiatric Hospital Population 10.26.09The Metabolic Syndrome in a State Psychiatric Hospital Population 10.26.09
The Metabolic Syndrome in a State Psychiatric Hospital Population 10.26.09
 
La struttura della medicina di precisione
La struttura della medicina di precisioneLa struttura della medicina di precisione
La struttura della medicina di precisione
 
Serum il17 and il6 levels in a sample of iraqi patients with rheumatoid arthr...
Serum il17 and il6 levels in a sample of iraqi patients with rheumatoid arthr...Serum il17 and il6 levels in a sample of iraqi patients with rheumatoid arthr...
Serum il17 and il6 levels in a sample of iraqi patients with rheumatoid arthr...
 
Avoidable Mortality and Health Disparities in the US 5.2.08
Avoidable Mortality and Health Disparities in the US 5.2.08Avoidable Mortality and Health Disparities in the US 5.2.08
Avoidable Mortality and Health Disparities in the US 5.2.08
 
ACC 2015
ACC 2015ACC 2015
ACC 2015
 
Polymorphisms rs1800587 and rs1143634 of the Interleukin-1α Gene are associat...
Polymorphisms rs1800587 and rs1143634 of the Interleukin-1α Gene are associat...Polymorphisms rs1800587 and rs1143634 of the Interleukin-1α Gene are associat...
Polymorphisms rs1800587 and rs1143634 of the Interleukin-1α Gene are associat...
 
Es v2n43
Es v2n43Es v2n43
Es v2n43
 
251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium
 

Similar to AHA NPAM EPI 2007 Abstract

Executive summary module 1
Executive summary module 1Executive summary module 1
Executive summary module 1
RioAlexsandro1
 
Executive summary module 1
Executive summary module 1Executive summary module 1
Executive summary module 1
RioAlexsandro1
 
BODY FAT DEPOSITION AND RISK FACTORS OF CARDIOVASCULAR DISEASES IN MEN
BODY FAT DEPOSITION AND RISK FACTORS OF CARDIOVASCULAR DISEASES IN MENBODY FAT DEPOSITION AND RISK FACTORS OF CARDIOVASCULAR DISEASES IN MEN
BODY FAT DEPOSITION AND RISK FACTORS OF CARDIOVASCULAR DISEASES IN MEN
Prof William Alves Lima
 
Cardiovascular diseases traditional_and_non-tradit
Cardiovascular diseases traditional_and_non-traditCardiovascular diseases traditional_and_non-tradit
Cardiovascular diseases traditional_and_non-tradit
ArhamSheikh1
 
Cardiac risk evaluation: searching for the vulnerable patient
Cardiac risk evaluation: searching for the vulnerable patient Cardiac risk evaluation: searching for the vulnerable patient
Cardiac risk evaluation: searching for the vulnerable patient
FELIX NUNURA
 
Dyslipidemia in stroke
Dyslipidemia in stroke  Dyslipidemia in stroke
Dyslipidemia in stroke
NeurologyKota
 
Risc cardiovascular i dislipèmies
Risc cardiovascular i dislipèmiesRisc cardiovascular i dislipèmies
Risc cardiovascular i dislipèmies
CAMFiC
 
Prevalence of Chronic Kidney disease in Patients with Metabolic Syndrome in S...
Prevalence of Chronic Kidney disease in Patients with Metabolic Syndrome in S...Prevalence of Chronic Kidney disease in Patients with Metabolic Syndrome in S...
Prevalence of Chronic Kidney disease in Patients with Metabolic Syndrome in S...
asclepiuspdfs
 
Examination of the incidence of heart disease in the US. A multivariate logis...
Examination of the incidence of heart disease in the US. A multivariate logis...Examination of the incidence of heart disease in the US. A multivariate logis...
Examination of the incidence of heart disease in the US. A multivariate logis...
AJHSSR Journal
 
HIGH SENSITIVE C-REACTIVE PROTEIN (hs-CRP) AND ITS CORRELATION WITH ANGIOGRAP...
HIGH SENSITIVE C-REACTIVE PROTEIN (hs-CRP) AND ITS CORRELATION WITH ANGIOGRAP...HIGH SENSITIVE C-REACTIVE PROTEIN (hs-CRP) AND ITS CORRELATION WITH ANGIOGRAP...
HIGH SENSITIVE C-REACTIVE PROTEIN (hs-CRP) AND ITS CORRELATION WITH ANGIOGRAP...
M A Hasnat
 
J dhaka med coll. 2010 19(2) 91 97.
J dhaka med coll. 2010  19(2) 91 97.J dhaka med coll. 2010  19(2) 91 97.
J dhaka med coll. 2010 19(2) 91 97.
DrMAHasnat
 
Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?
My Healthy Waist
 
id_08133649_Cardiovasculardisease.pptx
id_08133649_Cardiovasculardisease.pptxid_08133649_Cardiovasculardisease.pptx
id_08133649_Cardiovasculardisease.pptx
AdelSALLAM4
 
Chronic disease what comes after risk factor epidemiology
Chronic disease what comes after risk factor epidemiologyChronic disease what comes after risk factor epidemiology
Chronic disease what comes after risk factor epidemiology
emphemory
 
A comparative study for some atherogenic indices in sera of
A comparative study for some atherogenic indices in sera ofA comparative study for some atherogenic indices in sera of
A comparative study for some atherogenic indices in sera of
Alexander Decker
 
A comparative study for some atherogenic indices in sera of
A comparative study for some atherogenic indices in sera ofA comparative study for some atherogenic indices in sera of
A comparative study for some atherogenic indices in sera of
Alexander Decker
 
Atherosclerosis, pumpsandpipesmdhc
Atherosclerosis, pumpsandpipesmdhcAtherosclerosis, pumpsandpipesmdhc
Atherosclerosis, pumpsandpipesmdhc
tmhsweb
 
Niraj_Pandey_Summary_InvDiab
Niraj_Pandey_Summary_InvDiabNiraj_Pandey_Summary_InvDiab
Niraj_Pandey_Summary_InvDiab
Niraj Kumar Pandey
 
Erectile Dysfunction
Erectile DysfunctionErectile Dysfunction
Erectile Dysfunction
theheartofthematter
 
DM and Heart, What more can we do for patient heart.pdf
DM and Heart, What more can we do for patient heart.pdfDM and Heart, What more can we do for patient heart.pdf
DM and Heart, What more can we do for patient heart.pdf
SolidaSakhan
 

Similar to AHA NPAM EPI 2007 Abstract (20)

Executive summary module 1
Executive summary module 1Executive summary module 1
Executive summary module 1
 
Executive summary module 1
Executive summary module 1Executive summary module 1
Executive summary module 1
 
BODY FAT DEPOSITION AND RISK FACTORS OF CARDIOVASCULAR DISEASES IN MEN
BODY FAT DEPOSITION AND RISK FACTORS OF CARDIOVASCULAR DISEASES IN MENBODY FAT DEPOSITION AND RISK FACTORS OF CARDIOVASCULAR DISEASES IN MEN
BODY FAT DEPOSITION AND RISK FACTORS OF CARDIOVASCULAR DISEASES IN MEN
 
Cardiovascular diseases traditional_and_non-tradit
Cardiovascular diseases traditional_and_non-traditCardiovascular diseases traditional_and_non-tradit
Cardiovascular diseases traditional_and_non-tradit
 
Cardiac risk evaluation: searching for the vulnerable patient
Cardiac risk evaluation: searching for the vulnerable patient Cardiac risk evaluation: searching for the vulnerable patient
Cardiac risk evaluation: searching for the vulnerable patient
 
Dyslipidemia in stroke
Dyslipidemia in stroke  Dyslipidemia in stroke
Dyslipidemia in stroke
 
Risc cardiovascular i dislipèmies
Risc cardiovascular i dislipèmiesRisc cardiovascular i dislipèmies
Risc cardiovascular i dislipèmies
 
Prevalence of Chronic Kidney disease in Patients with Metabolic Syndrome in S...
Prevalence of Chronic Kidney disease in Patients with Metabolic Syndrome in S...Prevalence of Chronic Kidney disease in Patients with Metabolic Syndrome in S...
Prevalence of Chronic Kidney disease in Patients with Metabolic Syndrome in S...
 
Examination of the incidence of heart disease in the US. A multivariate logis...
Examination of the incidence of heart disease in the US. A multivariate logis...Examination of the incidence of heart disease in the US. A multivariate logis...
Examination of the incidence of heart disease in the US. A multivariate logis...
 
HIGH SENSITIVE C-REACTIVE PROTEIN (hs-CRP) AND ITS CORRELATION WITH ANGIOGRAP...
HIGH SENSITIVE C-REACTIVE PROTEIN (hs-CRP) AND ITS CORRELATION WITH ANGIOGRAP...HIGH SENSITIVE C-REACTIVE PROTEIN (hs-CRP) AND ITS CORRELATION WITH ANGIOGRAP...
HIGH SENSITIVE C-REACTIVE PROTEIN (hs-CRP) AND ITS CORRELATION WITH ANGIOGRAP...
 
J dhaka med coll. 2010 19(2) 91 97.
J dhaka med coll. 2010  19(2) 91 97.J dhaka med coll. 2010  19(2) 91 97.
J dhaka med coll. 2010 19(2) 91 97.
 
Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?Impact of obesity on cardiometabolic risk: Will we lose the battle?
Impact of obesity on cardiometabolic risk: Will we lose the battle?
 
id_08133649_Cardiovasculardisease.pptx
id_08133649_Cardiovasculardisease.pptxid_08133649_Cardiovasculardisease.pptx
id_08133649_Cardiovasculardisease.pptx
 
Chronic disease what comes after risk factor epidemiology
Chronic disease what comes after risk factor epidemiologyChronic disease what comes after risk factor epidemiology
Chronic disease what comes after risk factor epidemiology
 
A comparative study for some atherogenic indices in sera of
A comparative study for some atherogenic indices in sera ofA comparative study for some atherogenic indices in sera of
A comparative study for some atherogenic indices in sera of
 
A comparative study for some atherogenic indices in sera of
A comparative study for some atherogenic indices in sera ofA comparative study for some atherogenic indices in sera of
A comparative study for some atherogenic indices in sera of
 
Atherosclerosis, pumpsandpipesmdhc
Atherosclerosis, pumpsandpipesmdhcAtherosclerosis, pumpsandpipesmdhc
Atherosclerosis, pumpsandpipesmdhc
 
Niraj_Pandey_Summary_InvDiab
Niraj_Pandey_Summary_InvDiabNiraj_Pandey_Summary_InvDiab
Niraj_Pandey_Summary_InvDiab
 
Erectile Dysfunction
Erectile DysfunctionErectile Dysfunction
Erectile Dysfunction
 
DM and Heart, What more can we do for patient heart.pdf
DM and Heart, What more can we do for patient heart.pdfDM and Heart, What more can we do for patient heart.pdf
DM and Heart, What more can we do for patient heart.pdf
 

More from Robert Lowe

AHA NPAM EPI 2009 Abstract
AHA NPAM EPI 2009 AbstractAHA NPAM EPI 2009 Abstract
AHA NPAM EPI 2009 Abstract
Robert Lowe
 
AACVPR 2002
AACVPR 2002AACVPR 2002
AACVPR 2002
Robert Lowe
 
NAASO October 2003
NAASO October 2003NAASO October 2003
NAASO October 2003
Robert Lowe
 
NAASO 2005 Power Point
NAASO 2005 Power PointNAASO 2005 Power Point
NAASO 2005 Power Point
Robert Lowe
 
NAASO 2007 Abstract 2
NAASO 2007 Abstract 2NAASO 2007 Abstract 2
NAASO 2007 Abstract 2
Robert Lowe
 
NAASO 2007 Abstract 1
NAASO 2007 Abstract 1NAASO 2007 Abstract 1
NAASO 2007 Abstract 1
Robert Lowe
 
NAASO 2006 Abstract
NAASO 2006 AbstractNAASO 2006 Abstract
NAASO 2006 Abstract
Robert Lowe
 
NAASO October 2006
NAASO October 2006NAASO October 2006
NAASO October 2006
Robert Lowe
 
ACSM 2005
ACSM 2005ACSM 2005
ACSM 2005
Robert Lowe
 
AACVPR 2002 Presentation
AACVPR 2002 PresentationAACVPR 2002 Presentation
AACVPR 2002 Presentation
Robert Lowe
 
AACVPR 2002
AACVPR 2002AACVPR 2002
AACVPR 2002
Robert Lowe
 
AACVPR 2006
AACVPR 2006AACVPR 2006
AACVPR 2006
Robert Lowe
 
AACVPR 2003
AACVPR 2003AACVPR 2003
AACVPR 2003
Robert Lowe
 
AACVPR 2006
AACVPR 2006AACVPR 2006
AACVPR 2006
Robert Lowe
 
AACVPR 2000
AACVPR 2000AACVPR 2000
AACVPR 2000
Robert Lowe
 

More from Robert Lowe (15)

AHA NPAM EPI 2009 Abstract
AHA NPAM EPI 2009 AbstractAHA NPAM EPI 2009 Abstract
AHA NPAM EPI 2009 Abstract
 
AACVPR 2002
AACVPR 2002AACVPR 2002
AACVPR 2002
 
NAASO October 2003
NAASO October 2003NAASO October 2003
NAASO October 2003
 
NAASO 2005 Power Point
NAASO 2005 Power PointNAASO 2005 Power Point
NAASO 2005 Power Point
 
NAASO 2007 Abstract 2
NAASO 2007 Abstract 2NAASO 2007 Abstract 2
NAASO 2007 Abstract 2
 
NAASO 2007 Abstract 1
NAASO 2007 Abstract 1NAASO 2007 Abstract 1
NAASO 2007 Abstract 1
 
NAASO 2006 Abstract
NAASO 2006 AbstractNAASO 2006 Abstract
NAASO 2006 Abstract
 
NAASO October 2006
NAASO October 2006NAASO October 2006
NAASO October 2006
 
ACSM 2005
ACSM 2005ACSM 2005
ACSM 2005
 
AACVPR 2002 Presentation
AACVPR 2002 PresentationAACVPR 2002 Presentation
AACVPR 2002 Presentation
 
AACVPR 2002
AACVPR 2002AACVPR 2002
AACVPR 2002
 
AACVPR 2006
AACVPR 2006AACVPR 2006
AACVPR 2006
 
AACVPR 2003
AACVPR 2003AACVPR 2003
AACVPR 2003
 
AACVPR 2006
AACVPR 2006AACVPR 2006
AACVPR 2006
 
AACVPR 2000
AACVPR 2000AACVPR 2000
AACVPR 2000
 

Recently uploaded

K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
suvadeepdas911
 
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHYMERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
DRPREETHIJAMESP
 
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Kosmoderma Academy Of Aesthetic Medicine
 
10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations   10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations
Traumasoft LLC
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
Acute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdfAcute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdf
Jim Jacob Roy
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
rishi2789
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
Dr. Ahana Haroon
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Jim Jacob Roy
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
Dr. Jyothirmai Paindla
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
Earlene McNair
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
PsychoTech Services
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
Government Dental College & Hospital Srinagar
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
chiranthgowda16
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 

Recently uploaded (20)

K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
 
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHYMERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
 
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
 
10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations   10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
Acute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdfAcute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdf
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 

AHA NPAM EPI 2007 Abstract

  • 1. Control/Tracking Number: EPI-07-A-28-AHA Activity: Abstract Current Date/Time: 10/3/2006 4:02:55 PM Prediction of the Framingham Risk Score and Coronary Heart Disease Risk in Extremely Obese Individuals. Author Block: Robert C Lowe Sr., Jennifer Patzkowsky, Debbie Zimmerman, Polk County Schs, Winter Haven, FL; Phil Chen, Cognoscenti Health Inst, Orlando, FL Abstract: The Framingham Risk Score (FRS) is widely used as a 10-year estimate of an individual’s risk of death due to myocardial infarction (MI) and coronary heart disease (CHD). The variables in the FRS include age, total cholesterol (TC), HDL cholesterol (HDL), systolic blood pressure (SBP), treatment for hypertension, and cigarette smoking. Current thinking alludes to the development of CHD through risk factors associated wih the Metabolic Syndrome (MetS), i.e., elevated t triglycerides (TG), waist circumference (WC), blood pressure (BP), glucose (BG) and decreased HDL. In addition to the FRS, the ratio of TC to HDL cholesterol has been validated to estimate 10-year coronary heart disease risk (CHDR). The purpose of this study was to explore the relationship between MetS risk factors, FRS, and CHDR in individuals classified as extremely obese (EO). Seventy-three EO individuals (Age = 48 ± 9 yr; BMI = 40.7 ± 8.8) randomly selected to participate in a weight loss program were used in this study. Multiple biometric measures, including those variables for MS and FRS were measured or calculated. The data were analysed by multiple stepwise regression. Triglyceride (TG) was the best predictor of FRS from a subset of MetS variables (Model 1; F1,70 = 40.41, p <0.00), however, it was a poor fit (R2adj = 36%). The inclusion of HDL, TG, and WC produced the best fit for CHDR (Model 2; F3,68 = 26.35, p < 0.00) from the subset of MetS variables and accounted for slightly half of the variance (R2adj = 52%). Although both Model 1 and Model 2 were highly significant, they were not able to explain 64% and 48% of the model variance, respectively. Despite the MetS risk factors being implicated in the development of CVD and CHD, these results suggest that using MetS variables to predict the 10-year risk of dying from MI and CHD is not warranted. : Author Disclosure Block: R.C. Lowe, None; J. Patzkowsky, None; D. Zimmerman, None; P. Chen, None. Unlabeled/Unapproved Disclosure (Complete): Please Select: : There are no unlabeled/unapproved uses of drugs or products Category (Complete): Obesity Keywords (Complete): Physical activity ; Obesity ; Exercise Presentation Preference (Complete): Oral Awards (Complete): Connection Corner (Complete): : yes Payment (Complete): Your credit card order has been processed on Tuesday 3 October 2006 at 3:58 PM. Attached Files: No Files Attached Status: Complete